Co-Diagnostics, Inc. reports Q2 2026 revenue of $166K, narrowing net loss to $6.3M, and plans for Tuberculosis assay submission later this year.
Co-Diagnostics, Inc. reported Q2 2026 revenue of $166,000, a 2% increase from $163,000 in the same period last year but still reflecting the challenges of a limited revenue base. The company continues to focus on expanding its molecular diagnostics platform while managing operating expenses, as it gears up for potential commercialization amid ongoing net losses.
Key Takeaways
- Total revenue for the quarter reached $166,000, up 2% year-over-year, reflecting modest growth despite operational challenges.
- Net loss narrowed to $6.3 million, or $1.46 per share, compared to a net loss of $7.7 million, or $7.00 per share in Q2 2025.
- Operating expenses decreased to $6.3 million from $8.2 million year-over-year, driven primarily by lower general and administrative costs.
- Adjusted EBITDA loss improved to $5.8 million from a $7.2 million loss in the prior year, indicating better cost management.
- Cash and cash equivalents declined to $3.6 million from $11.9 million at the end of 2025, as the company continues to invest in clinical programs and platform development.
Modest Revenue Growth Amid Operational Challenges
Co-Diagnostics reported total revenue of $166,000 for Q2 2026, a slight increase from $163,000 in Q2 2025. The company is still grappling with a limited revenue base, which underscores the need for strategic advancements in its product offerings and market engagement. The modest revenue growth does indicate some progress, although it remains a small fraction of the company’s long-term goals.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $166,000 | +2% | N/A |
| Net Loss | $6.3 million | N/A | N/A |
| Operating Expenses | $6.3 million | -23% | N/A |
| Adjusted EBITDA | -$5.8 million | N/A | N/A |
Strategic Focus on Regulatory and Clinical Milestones
Management emphasized the importance of advancing regulatory strategies and clinical development during the earnings call. The company plans to submit its Tuberculosis assay for Emergency Use Authorization later this year, a significant step that could enhance its product portfolio. Additionally, Co-Diagnostics has made strides in developing an Ebola assay, which has garnered attention due to recent public health concerns.
“Our strategy with Ebola is designed to be ready when needed,” said Dwight Egan, CEO. “We were very quick to respond to the development need for an Ebola test.”
This proactive approach reflects the company’s commitment to addressing urgent health crises while expanding its diagnostic capabilities.
Strengthened Cost Management and Reduced Operating Expenses
Co-Diagnostics successfully decreased total operating expenses to $6.3 million in Q2 2026, down from $8.2 million in the same quarter last year. This reduction was primarily due to lower general and administrative expenses, including cuts in legal and personnel costs, as well as a decrease in stock-based compensation. The company’s disciplined expense management strategy has allowed it to mitigate losses despite limited revenue generation.
Cash Position and Future Funding Strategies
The company ended the quarter with $3.6 million in cash and cash equivalents, a decline from $11.9 million at the end of 2025. This decrease is largely attributed to ongoing investments in clinical programs and platform development. Management indicated that while they anticipate continued operating losses, they are focused on evaluating potential sources of capital, including equity or debt financing, to support key clinical and regulatory milestones.
“Our priorities remain clear, advancing our clinical pipeline, completing our regulatory submissions, and positioning the business for future revenue growth,” said Brian Brown, CFO.
Frequently Asked Questions
Did Co-Diagnostics, Inc. Common Stock beat earnings estimates in Q2 2026?
Co-Diagnostics reported a net loss of $1.46 per share, which was below analyst expectations. This reflects ongoing challenges in turning a profit as the company invests heavily in its diagnostic platform.
What were the total expenses for Co-Diagnostics in Q2 2026?
Total operating expenses for Co-Diagnostics in Q2 2026 were $6.3 million, significantly down from $8.2 million in Q2 2025, indicating improved cost management.
What is the cash position of Co-Diagnostics as of the end of Q2 2026?
As of the end of Q2 2026, Co-Diagnostics had $3.6 million in cash and cash equivalents, a notable decrease from $11.9 million at the end of 2025, reflecting ongoing investments in its clinical programs.
When does Co-Diagnostics plan to submit its Tuberculosis assay for ERPD assessment?
Co-Diagnostics confirmed plans to submit its Tuberculosis assay for Emergency Use Authorization later this year, aiming to enhance its product offerings in the diagnostics market.
The next quarter will be crucial for Co-Diagnostics as it seeks to navigate these challenges and capitalize on its strategic initiatives.
This analysis is based on public earnings call materials and is not investment advice.
